Steve Bryson, PhD,  science writer—

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Study IDs new potential immune targets in MPO-related AAV

Researchers have identified new contributors to the abnormal immune responses against the myeloperoxidase (MPO) enzyme that drive ANCA-associated vasculitis (AAV) in some patients. Specifically, these abnormal responses are marked by high numbers of memory B-cells that produce an antibody type called immunoglobulin M (IgM). Memory B-cells are immune cells crucial to…

AAV prevalence high among Indigenous peoples of Alaska: Study

The frequency of ANCA-associated vasculitis (AAV) among the Indigenous peoples of Alaska is high compared with other populations worldwide, especially the granulomatosis with polyangiitis (GPA) form of the disease,  a study reports. Native Alaskans and American Indians in Alaska with AAV also may have more severe clinical features at…

Scientists ID 4 MPA subtypes for better predicting patient outcomes

Researchers in Japan have identified four distinct subtypes of microscopic polyangiitis, or MPA — a type of ANCA-associated vasculitis (AAV) — that are associated with different clinical characteristics, which may help in better predicting, and improving, patient outcomes, according to the team. One subtype was marked mainly by kidney…

AI analysis of clinicians’ notes in medical records helps identify AAV

Machine learning based on clinicians’ notes found in electronic health records accurately identifies cases of ANCA-associated vasculitis (AAV), a study demonstrated. The model was found to be superior to traditional algorithms based on diagnostic codes with or without medication use at identifying AAV cases. “Its application to EHR [electronic…

Phase 3 trial of Tavneos enrolling children, ages 6-17, with AAV

A new Phase 3 clinical trial is recruiting children and adolescents with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), the most common types of ANCA-associated vasculitis (AAV), to test Tavneos (avacopan) in combination with rituximab or cyclophosphamide. That’s according to a financial update released by…

Low ceruloplasmin protein linked to worse survival in anti-MPO AAV

Low blood levels of the copper-carrying protein ceruloplasmin at diagnosis are associated with worse survival in adults with ANCA-associated vasculitis (AAV) who test positive for self-reactive antibodies against the myeloperoxidase (MPO) enzyme, a new study from France has shown. “This is the first study associating low [blood] ceruloplasmin level…

1 in 10 ANCA-positive people with lung disease develop AAV

About 1 in 10 people with idiopathic interstitial pneumonia (IIP), a condition marked by lung scarring of an unknown cause, who test positive for antineutrophil cytoplasmic antibodies, or ANCAs, eventually develop ANCA-associated vasculitis (AAV), a study shows. These patients’ risk factors for AAV include testing positive for ANCAs against…

NorthStar to sponsor sweeping AAV research program to improve care

NorthStar Medical Radioisotopes will sponsor an investigator-initiated research program focusing on the use of radioisotopes in diagnosing and treating ANCA-associated vasculitis (AAV), among other program goals. A radioisotope, or radioactive isotope, is an unstable form of a chemical element that releases radiation to return to a more stable…